Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 2

1(20.0%)

5Total

N/A(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07039955Not ApplicableEnrolling By Invitation

Effect of Daily Chlorhexidine Bathing and Antibiotic/PPI Stewardship on Prevention of CPE Transmission and Infection

Role: collaborator

NCT05058833Completed

Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function

Role: collaborator

NCT06138769Phase 2Active Not Recruiting

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

Role: collaborator

NCT04328987Completed

Safety of Cold Snare Polypectomy in Patients With Uninterrupted Antiplatelet Agent

Role: collaborator

NCT05708157Unknown

Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

Role: collaborator

NCT03181854Not ApplicableCompleted

Randomized Controlled Trial of Integrated Early Palliative Care

Role: collaborator

NCT03252678Not ApplicableCompleted

Efficacy of Self-education Program for Advanced Care Planning(RCT)

Role: collaborator

NCT03326375Not ApplicableUnknown

Comparison of SBRTand Repeat TACE for HCC

Role: lead

NCT02995798Completed

The Characteristics of Regional Bone Quality in the Cervical Vertebrae Considering BMD

Role: lead

All 9 trials loaded